NCT05640271View on ClinicalTrials.gov

Tocilizumab for Acute Chest Syndrome

PHASE2RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

January 31, 2027

Conditions

Sickle Cell DiseaseAcute Chest Syndrome

Interventions

DRUG

Tocilizumab

Tocilizumab 80 mg IV dose (one time per patient)

Trial Locations (1)

60637

RECRUITING

University of Chicago, Chicago

All Listed Sponsors

lead

University of Chicago

OTHER